A Translational Strategy to Evaluate ADC Efficacy & Overcome Payload-Specific Resistance Using Topo1 & Tubulin Inhibitor-Resistant PDX Models
- Assessing ADC efficacy through in vitro PDXO, MiniPDX, PDX models
- Establishing a unique panel of PDX models with data revealing resistance is driven by specific payload mechanism, independent of the target antigen
- Validating rational combinations including ADC + IO therapy to overcome immunosuppressive resistance
- Informing the design of next-generation ADCs, such as bispecific ADCs or dual-payload conjugates, engineered to circumvent these resistance pathways